iPSC-derived natural killer cell therapy - iCamuno Biotherapeutics
Alternative Names: iNK cell therapy- iCamuno BiotherapeuticsLatest Information Update: 12 Sep 2024
At a glance
- Originator iCamuno Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Ovarian cancer